Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.

Literature DB >> 31754884

Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.

Janelle Sobecki-Rausch¹, Lisa Barroilhet².

Abstract

OPINION STATEMENT: Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.

Entities: Disease Species

Keywords: Anti-PD-1 treatment; Endometrial cancer; Microsatellite instability; Mismatch repair deficiency; Pembrolizumab

Year: 2019 PMID： 31754884 DOI： 10.1007/s11864-019-0679-5

Source DB: PubMed Journal: Curr Treat Options Oncol ISSN： 1534-6277

30 in total

1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544

2. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors: Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal: J Clin Oncol Date: 2017-11-02 Impact factor: 44.544

3. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245

Review 4. Role of PD-1 in regulating T-cell immunity.

Authors: Hyun-Tak Jin; Rafi Ahmed; Taku Okazaki
Journal: Curr Top Microbiol Immunol Date: 2011 Impact factor: 4.291

Review 5. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701

Review 6. Microsatellite Instability as a Biomarker for PD-1 Blockade.

Authors: Jonathan C Dudley; Ming-Tseh Lin; Dung T Le; James R Eshleman
Journal: Clin Cancer Res Date: 2016-02-15 Impact factor: 12.531

7. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.

Authors: Anne M Mills; Sofia Liou; James M Ford; Jonathan S Berek; Reetesh K Pai; Teri A Longacre
Journal: Am J Surg Pathol Date: 2014-11 Impact factor: 6.394

8. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis).

Authors: Madhuri Hegde; Mathew Ferber; Rong Mao; Wade Samowitz; Arupa Ganguly
Journal: Genet Med Date: 2013-12-05 Impact factor: 8.822